{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:26:16Z","timestamp":1773447976362,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,12,31]],"date-time":"2014-12-31T00:00:00Z","timestamp":1419984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2014,12,31]],"date-time":"2014-12-31T00:00:00Z","timestamp":1419984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Elafin is an endogenous serine protease inhibitor. The majority of breast cancer cell lines lack elafin expression compared to human mammary epithelial cells. In this study, we hypothesized that elafin is downregulated during breast and ovarian tumorigenesis.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>We examined elafin expression by immunohistochemistry (IHC) in specimens of normal breast tissue (n = 24), ductal carcinoma <jats:italic>in situ<\/jats:italic> (DCIS) (n = 54), and invasive breast cancer (n = 793). IHC analysis of elafin expression was also performed in normal fallopian tube tissue (n = 20), ovarian cystadenomas (n = 9), borderline ovarian tumors (n = 21), and invasive ovarian carcinomas (n = 216). To understand the significance of elafin in luminal breast cancer cell lines, wild-type or M25G elafin (lacking the protease inhibitory function) were exogenously expressed in MCF-7 and T47D cells.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Elafin expression was downregulated in 24% of DCIS and 83% of invasive breast tumors when compared to elafin expression in the normal mammary epithelium. However, the presence of elafin-positive cells in invasive breast tumors, even at low frequency, correlated with poor recurrence-free survival (RFS), reduced overall survival (OS), and clinicopathological markers of aggressive tumor behavior. Elafin-positive cells were an especially strong and independent prognostic marker of reduced RFS in IHC-defined luminal A-like tumors. Elafin was also downregulated in 33% of ovarian cystadenomas, 43% of borderline ovarian tumors, and 86% of invasive ovarian carcinomas when compared to elafin expression in the normal fallopian tube. In ovarian tumors, elafin-positive cells were correlated with reduced RFS, OS and disease-specific survival (DSS) only in stage I\/II patients and not in stage III\/IV patients. Notably, exogenous expression of elafin or elafin M25G in the luminal breast cancer cell lines MCF-7 and T47D significantly decreased cell proliferation in a protease inhibitory domain-independent manner.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>Elafin predicts poor outcome in breast and ovarian cancer patients and delineates a subset of endocrine receptor-positive breast cancer patients susceptible to recurrence who could benefit from more aggressive intervention. Our <jats:italic>in vitro<\/jats:italic> results suggest that elafin arrests luminal breast cancer cells, perhaps suggesting a role in tumor dormancy.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/s13058-014-0497-4","type":"journal-article","created":{"date-parts":[[2014,12,30]],"date-time":"2014-12-30T13:43:45Z","timestamp":1419947025000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence"],"prefix":"10.1186","volume":"16","author":[{"given":"Joseph A","family":"Caruso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cansu","family":"Karakas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constance","family":"Albarracin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aysegul","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Bondy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinsong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly K","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khandan","family":"Keyomarsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,31]]},"reference":[{"issue":"25","key":"497_CR1","doi-asserted-by":"crossref","first-page":"14791","DOI":"10.1016\/S0021-9258(18)77182-2","volume":"265","author":"O Wiedow","year":"1990","unstructured":"Wiedow O, Schroder JM, Gregory H, Young JA, Christophers E: Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J Biol Chem. 1990, 265 (25): 14791-14795.","journal-title":"J Biol Chem"},{"key":"497_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/1471-2180-10-253","volume":"10","author":"A Bellemare","year":"2010","unstructured":"Bellemare A, Vernoux N, Morin S, Gagne SM, Bourbonnais Y: Structural and antimicrobial properties of human pre-elafin\/trappin-2 and derived peptides against Pseudomonas aeruginosa. BMC Microbiol. 2010, 10: 253-10.1186\/1471-2180-10-253.","journal-title":"BMC Microbiol"},{"issue":"1","key":"497_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1165\/ajrcmb.25.1.4341","volume":"25","author":"L Bingle","year":"2001","unstructured":"Bingle L, Tetley TD, Bingle CD: Cytokine-mediated induction of the human elafin gene in pulmonary epithelial cells is regulated by nuclear factor-kappaB. Am J Respir Cell Mol Biol. 2001, 25 (1): 84-91. 10.1165\/ajrcmb.25.1.4341.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"2","key":"497_CR4","doi-asserted-by":"publisher","first-page":"e4380","DOI":"10.1371\/journal.pone.0004380","volume":"4","author":"Z Wang","year":"2009","unstructured":"Wang Z, Chen F, Zhai R, Zhang L, Su L, Lin X, Thompson T, Christiani DC: Plasma neutrophil elastase and elafin imbalance is associated with acute respiratory distress syndrome (ARDS) development. PLoS One. 2009, 4 (2): e4380-10.1371\/journal.pone.0004380.","journal-title":"PLoS One"},{"issue":"158","key":"497_CR5","doi-asserted-by":"publisher","first-page":"158ra144","DOI":"10.1126\/scitranslmed.3004212","volume":"4","author":"JP Motta","year":"2012","unstructured":"Motta JP, Bermudez-Humaran LG, Deraison C, Martin L, Rolland C, Rousset P, Boue J, Dietrich G, Chapman K, Kharrat P, Vinel JP, Alric L, Mas E, Sallenave JM, Langella P, Vergnolle N: Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Sci Transl Med. 2012, 4 (158): 158ra144-10.1126\/scitranslmed.3004212.","journal-title":"Sci Transl Med"},{"issue":"4","key":"497_CR6","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1053\/j.gastro.2010.12.050","volume":"140","author":"JP Motta","year":"2005","unstructured":"Motta JP, Magne L, Descamps D, Rolland C, Squarzoni-Dale C, Rousset P, Martin L, Cenac N, Balloy V, Huerre M, Fr\u00f6hlich LF, Jenne D, Wartelle J, Belaaouaj A, Mas E, Vinel JP, Alric L, Chignard M, Vergnolle N, Sallenave JM: Modifying the protease, antiprotease pattern by elafin overexpression protects mice from colitis. Gastroenterology. 2005, 140 (4): 1272-1282. 10.1053\/j.gastro.2010.12.050.","journal-title":"Gastroenterology"},{"issue":"12","key":"497_CR7","first-page":"2537","volume":"55","author":"M Zhang","year":"1995","unstructured":"Zhang M, Zou Z, Maass N, Sager R: Differential expression of elafin in human normal mammary epithelial cells and carcinomas is regulated at the transcriptional level. Cancer Res. 1995, 55 (12): 2537-2541.","journal-title":"Cancer Res"},{"issue":"23","key":"497_CR8","doi-asserted-by":"publisher","first-page":"11272","DOI":"10.1158\/0008-5472.CAN-07-2322","volume":"67","author":"T Yokota","year":"2007","unstructured":"Yokota T, Bui T, Liu Y, Yi M, Hunt KK, Keyomarsi K: Differential regulation of elafin in normal and tumor-derived mammary epithelial cells is mediated by CCAAT\/enhancer binding protein beta. Cancer Res. 2007, 67 (23): 11272-11283. 10.1158\/0008-5472.CAN-07-2322.","journal-title":"Cancer Res"},{"issue":"18","key":"497_CR9","doi-asserted-by":"publisher","first-page":"7125","DOI":"10.1158\/0008-5472.CAN-10-1547","volume":"70","author":"JA Caruso","year":"2010","unstructured":"Caruso JA, Hunt KK, Keyomarsi K: The neutrophil elastase inhibitor elafin triggers rb-mediated growth arrest and caspase-dependent apoptosis in breast cancer. Cancer Res. 2010, 70 (18): 7125-7136. 10.1158\/0008-5472.CAN-10-1547.","journal-title":"Cancer Res"},{"issue":"1","key":"497_CR10","doi-asserted-by":"publisher","first-page":"R3","DOI":"10.1186\/bcr3374","volume":"15","author":"KK Hunt","year":"2013","unstructured":"Hunt KK, Wingate H, Yokota T, Liu Y, Mills GB, Zhang F, Fang B, Su CH, Zhang M, Yi M, Keyomarsi K: Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer. Breast Cancer Res. 2013, 15 (1): R3-10.1186\/bcr3374.","journal-title":"Breast Cancer Res"},{"issue":"10","key":"497_CR11","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1158\/1055-9965.EPI-12-0474","volume":"21","author":"R Haque","year":"2012","unstructured":"Haque R, Ahmed SA, Inzhakova G, Shi J, Avila C, Polikoff J, Bernstein L, Enger SM, Press MF: Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev. 2012, 21 (10): 1848-1855. 10.1158\/1055-9965.EPI-12-0474.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"497_CR12","doi-asserted-by":"publisher","first-page":"e23543","DOI":"10.1371\/journal.pone.0023543","volume":"6","author":"PA Thompson","year":"2011","unstructured":"Thompson PA, Brewster AM, Kim-Anh D, Baladandayuthapani V, Broom BM, Edgerton ME, Hahn KM, Murray JL, Sahin A, Tsavachidis S, Wang Y, Zhang L, Hortobagyi GN, Mills GB, Bondy ML: Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. PLoS One. 2011, 6 (8): e23543-10.1371\/journal.pone.0023543.","journal-title":"PLoS One"},{"issue":"3","key":"497_CR13","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/modpathol.2011.170","volume":"25","author":"J Zhang","year":"2012","unstructured":"Zhang J, Guo X, Chang DY, Rosen DG, Mercado-Uribe I, Liu J: CD133 expression associated with poor prognosis in ovarian cancer. Mod Pathol. 2012, 25 (3): 456-464. 10.1038\/modpathol.2011.170.","journal-title":"Mod Pathol"},{"issue":"2","key":"497_CR14","first-page":"155","volume":"11","author":"DC Allred","year":"1998","unstructured":"Allred DC, Harvey JM, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998, 11 (2): 155-168.","journal-title":"Mod Pathol"},{"issue":"1","key":"497_CR15","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1073\/pnas.87.1.463","volume":"87","author":"V Band","year":"1990","unstructured":"Band V, Zajchowski D, Kulesa V, Sager R: Human papilloma virus DNAs immortalize normal human mammary epithelial cells and reduce their growth factor requirements. Proc Natl Acad Sci U S A. 1990, 87 (1): 463-467. 10.1073\/pnas.87.1.463.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"497_CR16","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1073\/pnas.86.4.1249","volume":"86","author":"V Band","year":"1989","unstructured":"Band V, Sager R: Distinctive traits of normal and tumor-derived human mammary epithelial cells expressed in a medium that supports long-term growth of both cell types. Proc Natl Acad Sci U S A. 1989, 86 (4): 1249-1253. 10.1073\/pnas.86.4.1249.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"497_CR17","doi-asserted-by":"publisher","first-page":"e1002538","DOI":"10.1371\/journal.pgen.1002538","volume":"8","author":"MT Duong","year":"2012","unstructured":"Duong MT, Akli S, Wei C, Wingate HF, Liu W, Lu Y, Yi M, Mills GB, Hunt KK, Keyomarsi K: LMW-E\/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1\/2-mTOR pathway in breast cancer patients. PLoS Genet. 2012, 8 (3): e1002538-10.1371\/journal.pgen.1002538.","journal-title":"PLoS Genet"},{"issue":"7","key":"497_CR18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s004030100238","volume":"293","author":"M Vandermeeren","year":"2001","unstructured":"Vandermeeren M, Daneels G, Bergers M, van Vlijmen-Willems I, Pol A, Geysen J, Schalkwijk J: Development and application of monoclonal antibodies against SKALP\/elafin and other trappin family members. Arch Dermatol Res. 2001, 293 (7): 343-349. 10.1007\/s004030100238.","journal-title":"Arch Dermatol Res"},{"issue":"16","key":"497_CR19","doi-asserted-by":"crossref","first-page":"12028","DOI":"10.1016\/S0021-9258(19)50303-9","volume":"268","author":"HO Molhuizen","year":"1993","unstructured":"Molhuizen HO, Alkemade HA, Zeeuwen PL, de Jongh GJ, Wieringa B, Schalkwijk J: SKALP\/elafin: an elastase inhibitor from cultured human keratinocytes. Purification, cDNA sequence, and evidence for transglutaminase cross-linking. J Biol Chem. 1993, 268 (16): 12028-12032.","journal-title":"J Biol Chem"},{"issue":"3","key":"497_CR20","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/humrep\/den452","volume":"24","author":"AE King","year":"2009","unstructured":"King AE, Wheelhouse N, Cameron S, McDonald SE, Lee KF, Entrican G, Critchley HO, Horne AW: Expression of secretory leukocyte protease inhibitor and elafin in human fallopian tube and in an in-vitro model of Chlamydia trachomatis infection. Hum Reprod. 2009, 24 (3): 679-686. 10.1093\/humrep\/den452.","journal-title":"Hum Reprod"},{"key":"497_CR21","doi-asserted-by":"crossref","unstructured":"Neto EP, Fuhrich DG, Carson DD, Engel BJ, Savaris RF: Elafin Expression in Mucosa of Fallopian Tubes Is Altered by Hydrosalpinx. Reprod Sci 2014, 21(3):401\u2013407.","DOI":"10.1177\/1933719113497291"},{"key":"497_CR22","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 2012, 490(7418):61\u201370.","DOI":"10.1038\/nature11412"},{"issue":"6","key":"497_CR23","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ccr.2006.10.008","volume":"10","author":"RM Neve","year":"2006","unstructured":"Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006, 10 (6): 515-527. 10.1016\/j.ccr.2006.10.008.","journal-title":"Cancer Cell"},{"issue":"3","key":"497_CR24","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1042\/BJ20070020","volume":"405","author":"A Doucet","year":"2007","unstructured":"Doucet A, Bouchard D, Janelle MF, Bellemare A, Gagne S, Tremblay GM, Bourbonnais Y: Characterization of human pre-elafin mutants: full antipeptidase activity is essential to preserve lung tissue integrity in experimental emphysema. Biochem J. 2007, 405 (3): 455-463. 10.1042\/BJ20070020.","journal-title":"Biochem J"},{"issue":"18","key":"497_CR25","doi-asserted-by":"publisher","first-page":"7547","DOI":"10.1073\/pnas.1017300108","volume":"108","author":"AM Karst","year":"2011","unstructured":"Karst AM, Levanon K, Drapkin R: Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci U S A. 2011, 108 (18): 7547-7552. 10.1073\/pnas.1017300108.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"497_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1593\/neo.91542","volume":"12","author":"A Clauss","year":"2010","unstructured":"Clauss A, Ng V, Liu J, Piao H, Russo M, Vena N, Sheng Q, Hirsch MS, Bonome T, Matulonis U, Ligon AH, Birrer MJ, Drapkin R: Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. Neoplasia. 2010, 12 (2): 161-172.","journal-title":"Neoplasia"},{"issue":"6","key":"497_CR27","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1002\/ijc.25125","volume":"127","author":"KS Yu","year":"2010","unstructured":"Yu KS, Lee Y, Kim CM, Park EC, Choi J, Lim DS, Chung YH, Koh SS: The protease inhibitor, elafin, induces p53-dependent apoptosis in human melanoma cells. Int J Cancer. 2010, 127 (6): 1308-1320. 10.1002\/ijc.25125.","journal-title":"Int J Cancer"},{"issue":"7","key":"497_CR28","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/sj.bjc.6600813","volume":"88","author":"JA Foekens","year":"2003","unstructured":"Foekens JA, Ries C, Look MP, Gippner-Steppert C, Klijn JG, Jochum M: Elevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease. Br J Cancer. 2003, 88 (7): 1084-1090. 10.1038\/sj.bjc.6600813.","journal-title":"Br J Cancer"},{"issue":"11","key":"497_CR29","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1016\/S0021-9258(19)70805-9","volume":"255","author":"CL Mainardi","year":"1980","unstructured":"Mainardi CL, Dixit SN, Kang AH: Degradation of type IV (basement membrane) collagen by a proteinase isolated from human polymorphonuclear leukocyte granules. J Biol Chem. 1980, 255 (11): 5435-5441.","journal-title":"J Biol Chem"},{"key":"497_CR30","doi-asserted-by":"crossref","unstructured":"Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, Stolz DB, Land SR, Marconcini LA, Kliment CR, Jenkins KM, Beaulieu KA, Mouded M, Frank SJ, Wong KK, Shapiro SD: Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med 2010, 16(2):219\u2013223.,","DOI":"10.1038\/nm.2084"},{"issue":"13","key":"497_CR31","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1158\/0008-5472.CAN-11-4135","volume":"72","author":"EA Mittendorf","year":"2012","unstructured":"Mittendorf EA, Alatrash G, Qiao N, Wu Y, Sukhumalchandra P, St John LS, Philips AV, Xiao H, Zhang M, Ruisaard K, Clise-Dwyer K, Lu S, Molldrem JJ: Breast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anticancer adaptive immune response. Cancer Res. 2012, 72 (13): 3153-3162. 10.1158\/0008-5472.CAN-11-4135.","journal-title":"Cancer Res"},{"issue":"18","key":"497_CR32","doi-asserted-by":"publisher","first-page":"6254","DOI":"10.1128\/MCB.21.18.6254-6269.2001","volume":"21","author":"DC Porter","year":"2001","unstructured":"Porter DC, Zhang N, Danes C, McGahren MJ, Harwell RM, Faruki S, Keyomarsi K: Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol. 2001, 21 (18): 6254-6269. 10.1128\/MCB.21.18.6254-6269.2001.","journal-title":"Mol Cell Biol"},{"key":"497_CR33","doi-asserted-by":"crossref","unstructured":"Labidi-Galy SI, Clauss A, Ng V, Duraisamy S, Elias KM, Piao HY, Bilal E, Davidowitz RA, Lu Y, Badalian-Very G, Gy\u00f6rffy B, Kang UB, Ficarro S, Ganesan S, Mills GB, Marto JA, Drapkin R: Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. Oncogene 2015, 34(3):373\u201383.","DOI":"10.1038\/onc.2013.562"},{"issue":"3","key":"497_CR34","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.ygyno.2012.03.018","volume":"125","author":"H Wei","year":"2012","unstructured":"Wei H, Hellstrom KE, Hellstrom I: Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis. Gynecol Oncol. 2012, 125 (3): 727-733. 10.1016\/j.ygyno.2012.03.018.","journal-title":"Gynecol Oncol"}],"updated-by":[{"DOI":"10.1186\/s13058-015-0572-5","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2015,6,25]],"date-time":"2015-06-25T00:00:00Z","timestamp":1435190400000}}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-014-0497-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-014-0497-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-014-0497-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-014-0497-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:05:56Z","timestamp":1728921956000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-014-0497-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,31]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,12]]}},"alternative-id":["497"],"URL":"https:\/\/doi.org\/10.1186\/s13058-014-0497-4","relation":{"erratum":[{"id-type":"doi","id":"10.1186\/s13058-015-0572-5","asserted-by":"object"}]},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,31]]},"assertion":[{"value":"20 August 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"3417"}}